for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Russia's RDIF signs deal to produce Sputnik V vaccine in China

FILE PHOTO: Bottles of Russia's "Sputnik-V" COVID-19 vaccine are seen before inoculation at a clinic in Tver, Russia, October 12, 2020. REUTERS/Tatyana Makeyeva

MOSCOW (Reuters) - Russia’s RDIF sovereign wealth fund and China’s Shenzhen Yuanxing Gene-tech have agreed to produce over 60 million doses of Russia’s Sputnik V vaccine against COVID-19 in China, RDIF said on Monday.

RDIF, which is marketing Sputnik V globally, said that commercial production was due to start in May.

Reporting by Maria Kiselyova; writing by Tom Balmforth; editing by Louise Heavens

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up